US Veterinary Vaccines Market

The US veterinary vaccines market is projected to reach USD 6.50 billion by 2031, growing from USD 4.67 billion in 2026, at a CAGR of 6.8% during the forecast period.

Growth in the US veterinary vaccines market is stimulated by expansion in the companion animal population, rising pet ownership, increasing incidence of zoonotic diseases, and initiatives by government bodies to promote animal health. This, in turn, enhances the demand for preventive vaccination in companion animals and livestock. However, high costs associated with vaccine development, storage, and administration act as a hindrance to market growth to some extent. Effectively balancing these drivers and constraints will remain paramount for the sustainable development, availability, and adoption of veterinary vaccine solutions in the United States.

Some of the prominent players operating in the US veterinary vaccines market include Zoetis (US), Merck & Co., Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco (US), Virbac (France), Ceva (France), Phibro Animal Health Corporation (US), Hester Biosciences Limited (India), Neogen Corporation (US), HIPRA (Spain), and Vaxxinova International B.V. (Netherlands).

To know about the assumptions considered for the study download the pdf brochure

Zoetis (US)

Zoetis develops and manufactures animal health medicines and vaccines, along with diagnostic products, genetic tests, biodevices, and a range of services designed to meet the needs of veterinarians, livestock farmers, and companion animal owners. Zoetis discovers, develops, manufactures, and commercializes a wide portfolio of vaccines and medicines for livestock and companion animals. The company’s major product categories include Anti-infectives, Vaccines, Parasiticides, Dermatology, Medicated Feed Additives, Other Pharmaceuticals, Animal Health Diagnostics, Other Non-pharmaceuticals, and Contract Manufacturing & Human Health. Zoetis operates in North America, Europe, the Middle East & Africa, Latin America, and Asia Pacific. The company has robust R&D operations focused on vaccines, devices, data, digital, and other technological innovations.

Merck & Co., Inc. (US)

Merck & Co., Inc. is a global healthcare company that delivers innovative solutions for animal healthcare. The company operates through two divisions: Pharmaceutical and Animal Health. The Animal Health segment discovers, develops, manufactures, and markets a wide range of veterinary pharmaceutical & vaccine products for various animal species. The company operates in over 50 countries across North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. Merck focuses on inorganic growth strategies, such as acquisitions, agreements, and expansions, for its growth in the US veterinary vaccines market.

Boehringer Ingelheim International GmbH (Germany)

Boehringer Ingelheim International GmbH is engaged in the research, development, production, and sales of various pharmaceutical products. The company operates through four basic divisions, namely Human Pharma, Animal Health, Biopharmaceutical Contract Manufacturing, and Discontinued Operations. The company’s Animal Health division includes a wide range of biological, pharmaceutical, and natural care products for food-producing and companion animals. Its strategic partnerships and global reach enhance its ability to meet evolving market demands, positioning it as a leader in the competitive US veterinary vaccines sector. The company has 151 subsidiaries worldwide. In 2025, it achieved the milestone for vaccines by selling four billion doses.

Related Reports:

US veterinary vaccines Market by Type (Porcine, Poultry, Livestock, Companion Animals), Technology (Live Attenuated, Inactivated, Toxoid), Route of Administration (Intramuscular, Subcutaneous, Oral), End user (Hospitals, Clinics) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com